The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhavesh Dhirajlal Tanna
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bhavesh Dhirajlal Tanna, a non-promoter individual, has disclosed acquisition of 3,75,000 equity shares (7.75% of total share capital, 6.34% of diluted capital) of Ganga Pharmaceuticals Ltd on July 17, 2025, through conversion of warrants/preferential allotment. His holding in the company increased from 16,000 shares (0.33%) to 3,91,000 shares (8.08%). The company's total equity share base also expanded from 48,36,500 shares to 59,11,500 shares, indicating broader warrant conversions by multiple holders. The acquirer is not part of the promoter/promoter group and is not classified as an FII. This filing is required because the acquirer's stake crossed the 5% disclosure threshold under SAST Regulations.
A non-promoter individual now holds over 8% stake, which could indicate positive external investor interest, but the company remains a small-cap with limited public float. Shareholders should note the dilution from warrant conversions and monitor if this acquirer continues to build his position towards the 10% trigger level.